Compare INTS & HUIZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INTS | HUIZ |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 12.6M |
| IPO Year | 2021 | 2019 |
| Metric | INTS | HUIZ |
|---|---|---|
| Price | $3.13 | $2.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $18.67 | N/A |
| AVG Volume (30 Days) | 19.9K | ★ 514.9K |
| Earning Date | 11-05-2026 | 08-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.27 |
| Revenue Next Year | N/A | $11.13 |
| P/E Ratio | ★ N/A | $7.81 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $1.04 |
| 52 Week High | $8.06 | $3.83 |
| Indicator | INTS | HUIZ |
|---|---|---|
| Relative Strength Index (RSI) | 45.93 | 61.00 |
| Support Level | $3.10 | $1.52 |
| Resistance Level | $4.17 | $2.63 |
| Average True Range (ATR) | 0.29 | 0.21 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 58.00 | 56.38 |
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners. Geographically, the company is concentrated in PRC Mainland, Hong Kong and others segments.